A study  to evaluate efficacy and safety of the combined use of oral vicadrostat and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

• Participants with medical history of hypertension and on active pharmacological treatment

• Participants with medical history of T2DM and on active pharmacological treatment

• Established CV disease and on active pharmacological treatment.

  • Established cardiovascular disease includes at least one of the following: coronary artery disease, or peripheral artery disease, or cerebrovascular disease 

Further qualifications may apply.

Gain access to cutting-edge medications and treatments before they are widely available.

Our expert team is under the guidance of renowned endocrinologist, Dr. Anastasios Manessis.

We are highly focused on patient well-being and the highest ethical standards in clinical research.